用加速度计测量婴幼儿肺动脉高压患者体力活动
这项多中心前瞻性观察研究纳入0-6岁肺动脉高压(PAH)患儿与对照儿童,佩戴ActiGraph与FitBit设备14天,评估可行性、耐受性与依从性。结果显示佩戴天数两组无显著差异,PAH患儿步数更少、久坐更多、活动强度更低,心率变异性无显著差异。
要点
- 可穿戴加速度计在0-6岁PAH患儿中测量体力活动可行。
- PAH患儿步数、向量幅度计数更低,久坐活动更多,各强度活动更少。
- 两组佩戴天数与心率变异性无显著差异,需更大样本验证。
核心结论
- 使用可穿戴加速度计设备测量幼儿PAH患者体力活动及其他终点是可行的。
- PAH患儿较对照儿童体力活动更少、久坐更多,但心率变异性无显著差异。
研究设计与样本
- 多中心前瞻性观察研究,纳入0-6岁PAH患儿与无PAH对照儿童。
- 参与者清醒时在髋部佩戴ActiGraph wGT3X-BT、腕部佩戴FitBit Inspire,持续14天。
- 比较两组步数、每分钟向量幅度计数、活动强度、心率及心率变异性。
主要发现
- PAH患者多为功能分级II级(n=16,89%),入组时接受口服药物治疗。
- 完整数据获得率:符合条件ActiGraph参与者81%,FitBit参与者72%。
- PAH参与者较对照参与者步数更少、每分钟向量幅度计数更低、久坐活动更多、各强度体力活动更少。
- 两组心率变异性无统计学显著差异。
临床怎么用
- 在0-6岁PAH患儿中可考虑使用可穿戴加速度计客观评估体力活动。
- PAH患儿体力活动水平低于对照儿童,评估时应关注久坐行为与活动强度。
- 需更大规模研究确定体力活动与疾病严重度的关联,以筛选儿科临床试验终点。
局限性
- PAH患者多为功能分级II级且接受口服药物治疗,代表性有限。
- 原文未报告长期随访或体力活动与疾病严重度的关联分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the feasibility, tolerability, and adherence with wearable actigraphy devices among infants and children with pulmonary arterial hypertension (PAH). STUDY DESIGN: This multicenter, prospective, observational study included children ages 0-6 years with and without PAH. Participants wore the ActiGraph wGT3X-BT on the hip and FitBit Inspire on the wrist during waking hours for 14 days. Steps, vector magnitude counts per minute, activity intensity, heart rate, and heart rate variability were compared between groups. RESULTS: Forty-seven participants (18 PAH, 29 control) were enrolled from 10 North American sites. PAH patients were mostly functional class II (n = 16, 89%) and treated with oral medications at the time of enrollment. The number of wear days was not significantly different between the groups (ActiGraph: 10 [95% CI: 5.5, 12.2] in PAH vs 8 [4, 12] in control, P = .20; FitBit 13 [10, 13.8] in PAH vs 12 [8, 14] in control, P = .87). Complete data were obtained in 81% of eligible ActiGraph participants and 72% of FitBit participants. PAH participants demonstrated fewer steps, lower vector magnitude counts per minute, more sedentary activity, and less intense physical activity at all levels compared with control participants. No statistically significant differences in heart rate variability were demonstrated between the 2 groups. CONCLUSIONS: Measurement of physical activity and other end points using wearable actigraphy devices was feasible in young children with PAH. Larger studies should determine associations between physical activity and disease severity in young patients with PAH to identify relevant end points for pediatric clinical trials.
引用
- Avitabile CM, Yung D, Handler S, et al. Measurement of Physical Activity by Actigraphy in Infants and Young Children with Pulmonary Arterial Hypertension. J Pediatr. 2023. PMID: 37517653. doi:10.1016/j.jpeds.2023.113639
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。